Arthritis, Rheumatoid Clinical Trial
— DREAMEROfficial title:
Defining Stress REsilience And Mindfulness Effects in Rheumatoid Arthritis
This clinical trial will test a mindfulness program in individuals with rheumatoid arthritis (RA). The main goals of this pilot study are to: - Assess patient satisfaction with a mindfulness course - Identify barriers to participation in, or completion of, a mindfulness course - Gather initial information to understand how a mindfulness course impacts RA symptoms Participants will: - Complete online questionnaires - Attend two in-person study visits, involving a brief joint exam and blood draw - Roughly half the participants will have the chance to participate in an 8-week online mindfulness course - Roughly half the participants will be invited to participate in an online focus group following completion of the mindfulness course Researchers will compare those in the mindfulness course with those receiving standard care in preparation for a larger future study to see how mindfulness impacts stress and inflammation in individuals with RA.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | December 2025 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Physician-confirmed diagnosis of rheumatoid arthritis (RA) - Access to a web-enabled computer, smartphone, or tablet Exclusion Criteria: - RA disease activity in remission - Current regular mindfulness practice (> 20 minutes per week) - Inability to participate in an intensive 8-week online mindfulness course - Prior participation in a mindfulness-based stress reduction (MBSR) course |
Country | Name | City | State |
---|---|---|---|
United States | Osher Center for Integrative Health | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco | National Center for Complementary and Integrative Health (NCCIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Clinical Disease Activity Index (CDAI) | The CDAI, is a patient and provider composite tool that incorporates data from the patient global assessment, provider global assessment, 28 swollen joint count, and 28 tender joint count. It is a validated measure of RA disease activity that is recommended by the American College of Rheumatology for use in clinical practice and RA pharmaceutical trials. This is an exploratory outcome measure as the current study is not adequately powered to assess whether MBSR-RD is effective for improving clinical outcomes. | 8 weeks | |
Other | Disease Activity Score in 28 Joints (DAS-28) | The DAS-28 is a validated measure of disease activity that is frequently employed in RA pharmaceutical clinical trials. It incorporates data from the patient global assessment, provider global assessment, 28 swollen joint count, 28 tender joint count, and a laboratory measure of systemic inflammation from either the erythrocyte sedimentation rate (ESR) or c-reactive protein (CRP). This is an exploratory outcome measure as the current study is not adequately powered to assess whether MBSR-RD is effective for improving clinical outcomes. | change from baseline to 8 weeks | |
Other | Modified Rheumatoid Arthritis Disease Activity Index, 5-item (RADAI-5) | The RADAI-5 is a validated patient-reported assessment of RA disease activity that comprises five questions in a Likert format from 0 to 10. We will use a modified version of the RADAI-5 in which the period of recall is 2 weeks instead of 6 months. This is an exploratory outcome measure as the current study is not adequately powered to assess whether MBSR-RD is effective for improving clinical outcomes. | change from baseline to 8 weeks | |
Other | Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference, 4-Item Scale | The PROMIS Pain Interference scale measures the extent to which pain hinders an individual's engagement with physical, mental, cognitive, emotional, recreational, and social activities. This is an exploratory outcome measure as the current study is not adequately powered to assess whether MBSR-RD is effective for improving clinical outcomes. | change from baseline to 8 weeks | |
Other | Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue, 4-Item Scale | The PROMIS Fatigue scale measures the experience of fatigue and associated impact on daily life. This is an exploratory outcome measure as the current study is not adequately powered to assess whether MBSR-RD is effective for improving clinical outcomes. | change from baseline to 8 weeks | |
Other | Patient-Reported Outcomes Measurement Information System (PROMIS) Global Mindfulness, 13-item Scale | The PROMIS Mindfulness scale measures the capacity for present moment awareness. This is an exploratory outcome measure and will be used to determine whether mindfulness mediates improvements in clinical outcomes such as pain among participant in the active treatment group. | change from baseline to 8 weeks | |
Other | Perceived Stress Scale, 10-item | The perceived stress scale measures general perceptions of the degree to which situations in one's life are viewed as stressful. This is an exploratory outcome measure and will be used to determine whether changes in perceived stress mediate improvements in clinical outcomes such as pain among participant in the active treatment group. | change from baseline to 8 weeks | |
Other | Brief Resilience Scale | The Brief Resilience Scale measures the perceived ability to bounce back or recover from stress. This is an exploratory outcome measure and will be used to determine whether stress resilience mediates improvements in clinical outcomes such as pain among participant in the active treatment group. | change from baseline to 8 weeks | |
Primary | Patient Satisfaction as Assessed by CSQ-8, Adapted for DREAMER Study | A modified version of the 8-item Client Satisfaction Questionnaire (CSQ-8) will be used to evaluate acceptability of the mindfulness program by patients in the treatment group. A few of the words in the original CSQ-8 were changed to make the questions relevant to the mindfulness program. Scores on the CSQ-8 range from 8-32, with higher scores indicating greater satisfaction. Scores = 24 indicate adequate satisfaction. | 8 weeks | |
Secondary | MBSR Course Attendance (Intervention Adherence) | Intervention adherence will be operationalized as the percentage of participants who were randomized to the mindfulness group and attended at least six of the eight group sessions. | 8 weeks | |
Secondary | Percent of Study Completers (Study Retention) | Study retention will be operationalized as the number of participants who completed assessments (questionnaires and physician disease activity assessment) at the follow-up time-point divided by the number of participants who enrolled in the study, multiplied by 100. | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01682512 -
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT00539760 -
A Phase I Rheumatoid Arthritis Study in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03312465 -
Anatomical Shoulder Domelock System Study
|
||
Completed |
NCT01208181 -
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
|
Phase 3 | |
Completed |
NCT03254810 -
Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT01711814 -
A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
|
Phase 2 | |
Completed |
NCT03315494 -
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers
|
Phase 1 | |
Withdrawn |
NCT03241446 -
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
|
Phase 1 | |
Completed |
NCT02748785 -
MTX Discontinuation and Vaccine Response
|
Phase 4 | |
Completed |
NCT02553018 -
Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe
|
Phase 3 | |
Active, not recruiting |
NCT02260778 -
Treat-to-target in RA: Collaboration To Improve adOption and adhereNce
|
N/A | |
Completed |
NCT02569736 -
Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
|
||
Completed |
NCT01750931 -
This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
|
Phase 2 | |
Not yet recruiting |
NCT01154647 -
Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes
|
N/A | |
Withdrawn |
NCT01204138 -
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA
|
Phase 2 | |
Completed |
NCT00975130 -
Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
|
Phase 3 | |
Completed |
NCT00913458 -
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
|
Phase 4 | |
Completed |
NCT00973479 -
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
|
Phase 3 | |
Completed |
NCT00550446 -
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
|
Phase 2 | |
Completed |
NCT00660647 -
Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)
|
Phase 3 |